1. In women with BRCA-associated, newly diagnosed advanced ovarian cancer, olaparib significantly prolonged progression-free survival (PFS) at three years compared ...
Worldwide, more than 100 million women use hormonal methods of contraception. Combined oral contraceptives have previously shown an inverse relationship ...
Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial Chagas ...
1. Patients with stage 3 epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) in addition to cytoreductive surgery and ...
1. BRCA1 promoter methylation in normal white blood cells (WBCs) was linked to risk for high-grade serous ovarian cancer (HGSOC). ...
1. Among patients with platinum-sensitive recurrent ovarian cancer, those who received the PARP inhibitor niraparib demonstrated significantly increased progression-free survival ...
1. The overall incidence of ovarian mass malignancy was low. 2. Fine needle aspiration cytology (FNAC) had low sensitivity and ...
1. A weekly dosing regimen of Paclitaxel versus the standard dosing of Paclitaxel every 3 weeks, both administered with ...
1. In a proof-of-concept study of 35 patients with ovarian or endometrial cancer, the use of uterine cavity lavage successfully ...
1. In a phase III trial of 150 patients with epithelial ovarian cancer, the use of adjuvant hormone therapy was ...
